Robert L Ferris1, Yael Flamand2, Gregory S Weinstein3, Shuli Li2, Harry Quon4, Ranee Mehra5, Joaquin J Garcia6, Christine H Chung7, Maura L Gillison8, Umamaheswar Duvvuri1, Bert W O'Malley3, Enver Ozer9, Giovana R Thomas10, Wayne M Koch4, Neil D Gross8, R Bryan Bell11, Nabil F Saba12, Miriam Lango13, Eduardo Méndez14,15, Barbara Burtness16. 1. UPMC Hillman Cancer Center, Pittsburgh, PA. 2. Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, MA. 3. University of Pennsylvania, Philadelphia, PA. 4. Johns Hopkins University, Baltimore, MD. 5. University of Maryland, Baltimore, MD. 6. Mayo Clinic, Rochester, MN. 7. Moffitt Cancer Center, Tampa FL. 8. The University of Texas, MD Anderson Cancer Center, Houston, TX. 9. The Ohio State University, Columbus, OH. 10. University of Miami, Miami, FL. 11. Providence Cancer Institute, Portland, OR. 12. Winship Cancer Institute at Emory University, Atlanta, GA. 13. Fox Chase Cancer Center, Philadelphia, PA. 14. University of Washington, Seattle, WA. 15. Deceased. 16. Yale School of Medicine and Yale Cancer Center, New Haven, CT.
Abstract
PURPOSE: Definitive or postoperative chemoradiation (CRT) is curative for human papillomavirus-associated (HPV+) oropharynx cancer (OPC) but induces significant toxicity. As a deintensification strategy, we studied primary transoral surgery (TOS) and reduced postoperative radiation therapy (RT) in intermediate-risk HPV+ OPC. METHODS: E3311 is a phase II randomized trial of reduced- or standard-dose postoperative RT for resected stage III-IVa (American Joint Committee on Cancer-seventh edition) HPV+ OPC, determined by pathologic parameters. Primary goals were feasibility of prospective multi-institutional study of TOS for HPV+ OPC, and oncologic efficacy (2-year progression-free survival) of TOS and adjuvant therapy in intermediate-risk patients after resection. TOS plus 50 Gy was considered promising if the lower limit of the exact 90% binomial confidence intervals exceeded 85%. Quality of life and swallowing were measured by functional assessment of cancer therapy-head and neck and MD Anderson Dysphagia Index. RESULTS: Credentialed surgeons performed TOS for 495 patients. Eligible and treated patients were assigned as follows: arm A (low risk, n = 38) enrolled 11%, intermediate risk arms B (50 Gy, n = 100) or C (60 Gy, n = 108) randomly allocated 58%, and arm D (high risk, n = 113) enrolled 31%. With a median 35.2-month follow-up for 359 evaluable (eligible and treated) patients, 2-year progression-free survival Kaplan-Meier estimate is 96.9% (90% CI, 91.9 to 100) for arm A (observation), 94.9% (90% CI, 91.3 to 98.6]) for arm B (50 Gy), 96.0% (90% CI, 92.8 to 99.3) for arm C (60 Gy), and 90.7% (90% CI, 86.2 to 95.4) for arm D (66 Gy plus weekly cisplatin). Treatment arm distribution and oncologic outcome for ineligible or step 2 untreated patients (n = 136) mirrored the 359 evaluable patients. Exploratory comparison of functional assessment of cancer therapy-head and neck total scores between arms B and C is presented. CONCLUSION: Primary TOS and reduced postoperative RT result in outstanding oncologic outcome and favorable functional outcomes in intermediate-risk HPV+ OPC.
PURPOSE: Definitive or postoperative chemoradiation (CRT) is curative for human papillomavirus-associated (HPV+) oropharynx cancer (OPC) but induces significant toxicity. As a deintensification strategy, we studied primary transoral surgery (TOS) and reduced postoperative radiation therapy (RT) in intermediate-risk HPV+ OPC. METHODS: E3311 is a phase II randomized trial of reduced- or standard-dose postoperative RT for resected stage III-IVa (American Joint Committee on Cancer-seventh edition) HPV+ OPC, determined by pathologic parameters. Primary goals were feasibility of prospective multi-institutional study of TOS for HPV+ OPC, and oncologic efficacy (2-year progression-free survival) of TOS and adjuvant therapy in intermediate-risk patients after resection. TOS plus 50 Gy was considered promising if the lower limit of the exact 90% binomial confidence intervals exceeded 85%. Quality of life and swallowing were measured by functional assessment of cancer therapy-head and neck and MD Anderson Dysphagia Index. RESULTS: Credentialed surgeons performed TOS for 495 patients. Eligible and treated patients were assigned as follows: arm A (low risk, n = 38) enrolled 11%, intermediate risk arms B (50 Gy, n = 100) or C (60 Gy, n = 108) randomly allocated 58%, and arm D (high risk, n = 113) enrolled 31%. With a median 35.2-month follow-up for 359 evaluable (eligible and treated) patients, 2-year progression-free survival Kaplan-Meier estimate is 96.9% (90% CI, 91.9 to 100) for arm A (observation), 94.9% (90% CI, 91.3 to 98.6]) for arm B (50 Gy), 96.0% (90% CI, 92.8 to 99.3) for arm C (60 Gy), and 90.7% (90% CI, 86.2 to 95.4) for arm D (66 Gy plus weekly cisplatin). Treatment arm distribution and oncologic outcome for ineligible or step 2 untreated patients (n = 136) mirrored the 359 evaluable patients. Exploratory comparison of functional assessment of cancer therapy-head and neck total scores between arms B and C is presented. CONCLUSION: Primary TOS and reduced postoperative RT result in outstanding oncologic outcome and favorable functional outcomes in intermediate-risk HPV+ OPC.
Authors: George Garas; Nick J Roland; Jeffrey Lancaster; Matthew Zammit; Victoria A Manon; Katharine Davies; Terry M Jones; Mriganka De; Floyd C Holsinger; Robin J D Prestwich; Jason C Fleming Journal: Ann Surg Oncol Date: 2022-07-16 Impact factor: 4.339
Authors: Sallie M Long; Annu Singh; Amy L Tin; Bridget O'Hara; Marc A Cohen; Nancy Lee; David G Pfister; Tony Hung; Richard J Wong; Andrew J Vickers; Cherry L Estilo; Jennifer R Cracchiolo Journal: JAMA Otolaryngol Head Neck Surg Date: 2022-08-01 Impact factor: 8.961
Authors: Chloe S Lalonde; Yong Teng; Barbara A Burtness; Robert L Ferris; Rafi Ahmed; Nabil F Saba Journal: J Natl Cancer Inst Date: 2022-10-06 Impact factor: 11.816
Authors: Nicolette Taku; Kareem A Wahid; Lisanne V van Dijk; Jaakko Sahlsten; Joel Jaskari; Kimmo Kaski; Clifton D Fuller; Mohamed A Naser Journal: Clin Transl Radiat Oncol Date: 2022-06-18